GXDX:
I've been watching Genoptix (GXDX) getting hammered for more than 6 months. This is a genetics testing lab specializing in Hemonc. They've disappointed on revenues and earnings and recently guided lower (stating that the weak economy is "affecting physician and patient behavior") but is still nicely profitable and now about 60% off its 52 week high.
I'm curious if anyone else follows GXDX, whether or not you have an opinion about their excuse for lowering their estimate (it sounds more like a euphemism for "competition is eating our lunch"), and if this seems to be an emerging biotech value, as their EPS is now looking like it will be single digit, or close to it, in a space that should be growing at a 20-25% YOY clip.
regards,
aj
